Navigation Links
ApoDIRECT DNA Fragmentation Assay Kit from MBL International

ProductsApoDIRECT DNA Fragmentation Assay Kit from MBL International
Company MBL International
Item ApoDIRECT DNA Fragmentation Assay Kit
Price 
Description 50 assays. The TUNEL-based assay kit provides complete components including positive and negative control cells for convenient detection of DNA fragmentation in cultured cells and tissue sections. The assay offers an one-step labeling of apoptotic cells.

Internucleosomal DNA fragmentation is a hallmark of apoptosis in mammalian cells. MBLs ApoDIRECT In Situ DNA Fragmentation Assay Kit provides complete components including positive and negative control cells for conveniently detecting DNA fragmentation by fluorescence microscopy or flow cytometry. The TUNEL-based detection kit utilizes terminal deoxynucleotidyl transferase (TdT) to catalyze incorporation of fluorescein-12-dUTP at the free 3-hydroxyl ends of the fragmented DNA. The fluorescein-labeled DNA can then be observed by fluorescence microscopy or analyzed by flow cytometry.
Info MBL InternationalMBL International
15 B Constitution Way
Woburn, MA 01801
Customer Service: 781-939-6964
Fax Number: 781-939-6963
Web Site: http://mblintl.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. ApoBrdU DNA Fragmentation Assay Kit from MBL International
2. ApoBrdU Red DNA Fragmentation Kit from MBL International
3. Glutathione-S-Transferase (GST) Colorimetric Assay Kit from Sigma-Aldrich
4. In Vitro Osteogenesis Assay Kit from CHEMICON
5. Mast Cell Degranulation colorimetric Assay Kit from CHEMICON
6. PR Competitor Assay Green from Invitrogen
7. PolarScreen Androgen Receptor Competitor Assay Kit, Red from Molecular Probes (Invitrogen)
8. Hydrogen Peroxide / Peroxidase Fluorometric (resorufin) Assay Kit, Fluoro H2O2 from BACHEM
9. PPARGamma-Competitor Assay Kit Green from Invitrogen
10. Total antioxidant capacity Colorimetric Assay Kit from Neogen Corporation
11. PolarScreen Progesterone Receptor Competitor Assay Kit, Far Red from Molecular Probes (Invitrogen)
Collected from animals that are 16 to 18 months old. Sterile, Cell culture tested, ID clarifier: USA Origin...
... 20-HETE is a cytochrome P450 (CYP450) metabolite ... the renal and cerebral vasculature. In rat ... mediates pressure-induced autoregulatory vasoconstriction. 20-HETE is excreted ... of free 20-HETE (20-40 pg/ml in human ...
... GPS-M Mutagenesis System enables you to insert ... into,your target DNA by in vitro transposition. ... Tn7-based,transposon randomly into the DNA target. Target ... or purified,chromosomal DNA, depending on your interests ...
A set of five peptides which can be used to calibrate a Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or Electrospray Ionization (ESI) mass spectrometer....
Biology Products:
(Date:2/9/2015)... 9, 2015  Lintec of America recently announced an ... nanotube (CNT) macrostructures, including sheets, yarns and ribbons, developed ... Leveraging the vast industrial resources of the global ... , Lintec of America is forming the Nano-Science and ... , focusing on scaling up the manufacturing and commercialization ...
(Date:2/5/2015)... Conn. , Jan. 26, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... new corporate website ( http://www.nxt-id.com/ ) as part of ... smart wallet. The Company launched its new consumer website ... Gino Pereira , CEO of NXT-ID said, "Our new ...
(Date:2/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6lngtl/global_biometrics ... "Global Biometrics Market (2014-2020): Market Forecast By Technologies, ... to their offering. , In ... is anticipated to overtake North America ... spending towards IT security, government biometric based projects ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3
... may not be the only organisms endangered by some food ... health risks to humans who eat meat from chickens that ... the April 9 issue of Chemical & Engineering News, the ... Roxarsone, the most common arsenic-based additive used in chicken feed, ...
... As people age, they may have to exercise even harder ... suggestion of a report in the February issue of the ... signal that gives muscles a kind of metabolic boost in ... researchers found that so-called AMP-activated protein kinase (AMPK) slows down ...
... to repair the human body, replacing defective and worn ... the body does not always accept such substitutes seamlessly. ... simply changing the surface texture of implants can dramatically ... materials. , Two recent experiments have focused on ...
Cached Biology News:Power-boosting signal in muscle declines with age 2Nanotextured implant materials: blending in, not fighting back 2Nanotextured implant materials: blending in, not fighting back 3
(Date:3/4/2015)... 2015 AcelRx Pharmaceuticals, Inc. (Nasdaq: ... on the development and commercialization of innovative therapies ... today announced that it will release fourth quarter ... on Monday, March 9th, 2015. AcelRx management will ... Eastern Time (1:30 p.m. Pacific Time) on March ...
(Date:3/4/2015)... PARIS , March 4, 2015 ... de Paris in December 2011, ... study of yttrium-90 resin microspheres versus sorafenib in advanced ... results expected late 2016.   SARAH, a ... liver cancer (hepatocellular carcinoma, or HCC) has completed patient ...
(Date:3/3/2015)... Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... Miami, FL on March 10, 2015 at 1:05 ... Financial Officer, will provide a corporate overview. The ... corporate website at www.halozyme.com , and a recording will ... access the live webcast, please log on to Halozyme,s website ...
(Date:3/3/2015)... , Mar. 03, 2015 Research and Markets ... the "Gene Therapy Market, 2015 - 2025" ... Therapy Market, 2015-2025" report provides an extensive study on ... research has been carried out in this field for ... therapies (four available in Asian markets; one approved in ...
Breaking Biology Technology:AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7